All In Biotech

Drug Trial Radar · NCT06972732

A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

A Randomized, Open-label, Active-controlled, Parallel, Multicenter, Phase IV Clinical Trial to Compare the Efficacy and Safety of Switching Metformin+SGLT2-i+Dipeptidyl Peptidase-4-inhibitor(DPP-4-i) to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

204

Planned (sponsor's estimate)

Start

Jun 11, 2025

Primary completion

Oct 1, 2026

Study completion Oct 1, 2026

Sponsor

Sponsor type
Industry
First posted
May 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.

Conditions

  • Type 2 Diabetes

Interventions

  • MetforminDrug

    The dosage and dose frequency are maintained as they were before the screening.

  • Dapagliflozin/PioglitazoneDrug

    Dapagliflozin 10mg/Pioglitazone 30mg QD

  • Dapagliflozin/SitagliptinDrug

    Dapagliflozin 10mg/Sitagliptin 100mg QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1c (%) change at 24 weeks compared to the baseline (Visit 2)Time frame: From baseline to end of treatment at 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, Seocho District, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.